Suppr超能文献

评估炎症细胞因子和单核细胞趋化蛋白-1(MCP-1)在预测高血压患者中风中的变异性及作用:一项病例对照研究。

Assessing the variability and the role of inflammatory cytokines and monocyte chemoattractant protein-1 (MCP-1) in predicting stroke among hypertensives: A case-control study.

作者信息

Sakyi Samuel Asamoah, Opoku Afia Serwaa, Amoani Benjamin, Afranie Bright Oppong, Kwarteng Alexander, Ephriam Richard Dadzie, Opoku Stephen, Senu Ebenezer, Aidoo Ebenezer, Sarfo Fred Stephen

机构信息

Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

Department of Biomedical Science, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.

出版信息

Dialogues Health. 2022 Nov 24;1:100086. doi: 10.1016/j.dialog.2022.100086. eCollection 2022 Dec.

Abstract

BACKGROUND

Atherosclerosis is a complex lipid-driven inflammatory disease in which numerous cell types and inflammatory mediators are involved in the progression of hypertension to stroke. Mediators' markers that could predict the progression of hypertension to stroke are of research importance. We assessed the predictive value of individual and combined cytokines and monocyte chemoattractant protein-1 (MCP-1) among hypertensives with or without stroke.

METHODS

In a case-control study, we enrolled 63 cases with stroke and hypertension (HPT-S), 59 stroke-free hypertensives (HPT), and 53 stroke free normotensives as controls (CS). Sociodemographic data and blood samples were collected for the estimation of Interleukin-10 (IL-10), IL-6, IL-8, IL-1β and monocyte chemoattractant protein-1 (MCP-1) using commercially available ELISA kits from Biobase Biotech, Shanghai, China. The Receiver Operator Characteristics (ROC) analysis was used to calculate diagnostic accuracy for cytokines in predicting stroke among hypertensives. A combined bioscore model of IL-10 and MCP-1 was generated to predict stroke among hypertensives. The multiple logistic regression analysis was used to assess the chances of IL-10 and MCP-1 in predicting stroke among hypertensives. Statistical analyses were performed using R-language.

RESULTS

The HPT-S group had significantly higher levels of MCP-1 and IL-10 compared to the HPT and CS groups (p < 0.05). There was no significant difference in IL-1β, IL-8 and IL-6 amongst the three study groups. MCP-1 and IL-10 were predictive of stroke occurrence among hypertensives and were used to develop a bioscore model. An elevated MCP-1 and IL-10 with a bioscore 2 had a predictive accuracy of 0.81, a sensitivity of 0.77 and specificity of 0.84. At a bioscore of 1, the sensitivity and specificity for predicting stroke among hypertensives was 97.0% and 61.0% respectively. In a binary logistic regression, having a bioscore of 1 [aOR = 20.43, 95% CI (2.17-192.62), = 0.008] or 2 [aOR = 26.00, 95% CI (2.92-231.31), = 0.003] were significantly associated with stroke occurrence among hypertensives.

CONCLUSION

Higher levels of IL-10 with a concomitant level of MCP-1 could serve as a good predictor of stroke among hypertensives. Subsequently, MCP-1 may prove useful as a therapeutic target for atherosclerosis in hypertensives. Combined bioscore of MCP-1 and IL-10 could serve as a good predictor of stroke among hypertensives.

摘要

背景

动脉粥样硬化是一种复杂的脂质驱动的炎症性疾病,其中多种细胞类型和炎症介质参与高血压发展为中风的过程。能够预测高血压发展为中风的介质标志物具有研究意义。我们评估了有或无中风的高血压患者中单个及联合细胞因子和单核细胞趋化蛋白-1(MCP-1)的预测价值。

方法

在一项病例对照研究中,我们纳入了63例中风合并高血压患者(HPT-S)、59例无中风的高血压患者(HPT)和53例无中风的血压正常者作为对照(CS)。收集社会人口学数据和血液样本,使用中国上海博科生物技术公司的商用ELISA试剂盒检测白细胞介素-10(IL-10)、IL-6、IL-8、IL-1β和单核细胞趋化蛋白-1(MCP-1)。采用受试者工作特征(ROC)分析来计算细胞因子预测高血压患者中风的诊断准确性。构建了IL-10和MCP-1的联合生物评分模型以预测高血压患者的中风。采用多因素逻辑回归分析评估IL-10和MCP-1预测高血压患者中风的可能性。使用R语言进行统计分析。

结果

与HPT组和CS组相比,HPT-S组的MCP-1和IL-10水平显著更高(p < 0.05)。三个研究组之间的IL-1β、IL-8和IL-6无显著差异。MCP-1和IL-10可预测高血压患者中风的发生,并用于构建生物评分模型。生物评分2时,MCP-1和IL-10升高的预测准确性为0.81,敏感性为0.77,特异性为0.84。生物评分为1时,预测高血压患者中风的敏感性和特异性分别为97.0%和61.0%。在二元逻辑回归中,生物评分为1 [调整后比值比(aOR) = 20.43,95%置信区间(CI)(2.17 - 192.62),p = 0.008] 或2 [aOR = 26.00,95% CI(2.92 - 231.31),p = 0.003] 与高血压患者中风的发生显著相关。

结论

较高水平的IL-10与MCP-1水平同时升高可作为高血压患者中风的良好预测指标。随后,MCP-1可能被证明是高血压患者动脉粥样硬化的有用治疗靶点。MCP-1和IL-!0的联合生物评分可作为高血压患者中风的良好预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a8c/10953871/a8bd3aacefb3/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验